Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for...

Area of Science:

• Pediatrics
• Infectious Diseases
• Vaccinology

Background:

• Invasive pneumococcal disease (IPD) remains a significant cause of childhood morbidity and mortality globally.
• Streptococcus pneumoniae serotypes causing IPD vary and evolve, necessitating ongoing surveillance.
• The development of pneumococcal conjugate vaccines (PCVs) aims to reduce the burden of IPD.

Purpose of the Study:

• To assess the incidence, clinical spectrum, and outcomes of IPD in children.
• To identify key Streptococcus pneumoniae serogroups responsible for pediatric IPD.
• To evaluate the potential serogroup coverage of novel pneumococcal conjugate vaccines.

Main Methods:

• Prospective analysis of all children admitted with IPD to two Nottingham teaching hospitals from 1980 to 1999.
• Data collection included clinical manifestations, age-specific incidence rates, mortality, and neurological sequelae.
• Serotype distribution and projected vaccine coverage were determined.

Main Results:

• 266 IPD episodes were identified; 60% of children were under 2 years old.
• Meningitis (32%), pneumonia (31%), and bacteremia (30%) were the primary clinical presentations.
• Incidence rates were highest in infants under 1 year (47.1/100,000). Mortality was 20% for meningitis and 7% for non-meningitic infections, with 26% of meningitis survivors experiencing neurological sequelae.
• PCVs demonstrated high potential coverage: 84% (7-valent), 91% (9-valent), and 95% (11-valent).

Conclusions:

• IPD poses a substantial risk to children, particularly those under two years.
• The study highlights the significant impact of IPD on pediatric mortality and morbidity.
• Incorporating PCVs into routine UK immunization programs could substantially decrease IPD-related mortality and morbidity.